keyword
MENU ▼
Read by QxMD icon Read
search

NAFLD fibrosis score

keyword
https://www.readbyqxmd.com/read/28199729/spectrum-of-disease-associated-with-partial-lipodystrophy-pl-lessons-from-a-trial-cohort
#1
Nevin Ajluni, Rasimcan Meral, Adam H Neidert, Graham F Brady, Eric Buras, Barbara McKenna, Frank DiPaola, Thomas L Chenevert, Jeffrey F Horowitz, Colleen Buggs-Saxton, Amit R Rupani, Peedikayil E Thomas, Marwan K Tayeh, Jeffrey W Innis, M Bishr Omary, Hari Conjeevaram, Elif A Oral
CONTEXT: Partial lipodystrophy (PL) is associated with metabolic co-morbidities but may go undiagnosed as the disease spectrum is not fully described. OBJECTIVE: Define disease spectrum in PL using genetic, clinical (historical, morphometric) and laboratory characteristics. DESIGN: Cross-sectional evaluation. PARTICIPANTS: 23 patients (22 with familial, one acquired, 78.3% female, aged 12-64 years) with PL and non-alcoholic fatty liver disease (NAFLD)...
February 15, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28195177/prevalence-of-nonalcoholic-steatohepatitis-associated-cirrhosis-in-the-united-states-an-analysis-of-national-health-and-nutrition-examination-survey-data
#2
Mohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, Kymberly Watt, Rocio Lopez, Zade Akras, Nizar Zein, William Carey, Naim Alkhouri
OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of manifestations ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis. The prevalence of NAFLD has been shown to be increasing over time; however, the prevalence of NASH cirrhosis and advanced fibrosis over time has not been well studied. Estimate the changes in prevalence of NASH cirrhosis and NAFLD-associated advanced fibrosis among adults in the United States...
February 14, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28179090/protective-role-of-soluble-receptor-for-advanced-glycation-end-products-in-patients-with-non-alcoholic-fatty-liver-disease
#3
Shira Zelber-Sagi, Federico Salomone, Ilana Kolodkin-Gal, Noam Erez, Assaf Buch, Hanny Yeshua, Muriel Webb, Zamir Halpern, Oren Shibolet
BACKGROUND: Soluble receptor for advanced glycation end-products (sRAGE) exerts protective metabolic effects. AIMS: To identify if sRAGE plays a protective role in NAFLD. METHODS: sRAGE (n=55) and Nε-(Carboxymethyl) lysine (CML) (n=36) serum levels were measured in NAFLD patients. Liver steatosis and fibrosis were non-invasively quantified by the hepatorenal index and the NAFLD fibrosis score (NFS). RESULTS: sRAGE levels were lower in NAFLD patients compared to controls (1207±439 vs...
January 19, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28104990/sitagliptin-in-patients-with-non-alcoholic-steatohepatitis-a-randomized-placebo-controlled-trial
#4
Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra, Melanie D Beaton
AIM: To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH). METHODS: Twelve patients with biopsy-proven NASH were randomized to sitagliptin (100 mg daily) (n = 6) or placebo (n = 6) for 24 wk. The primary outcome was improvement in liver fibrosis after 24 wk. Secondary outcomes included evaluation of changes in NAFLD activity score (NAS), individual components of NAS (hepatocyte ballooning, lobular inflammation, and steatosis), glycemic control and insulin resistance [including measurements of glycated hemoglobin (HbA1C) and adipocytokines], lipid profile including free fatty acids, adipose distribution measured using magnetic resonance imaging (MRI), and thrombosis markers (platelet aggregation and plasminogen activator inhibitor 1 levels)...
January 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28073147/treating-nonalcoholic-steatohepatitis-nash-in-children-not-a-cinch-task
#5
Naim Alkhouri, Ariel E Feldstein
BACKGROUND & AIMS: No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD. METHODS: We performed a double-masked trial of 169 children with NAFLD Activity Scores ≥ 4 at 10 centers. From June 2012 to January 2014, the patients were randomly assigned to receive CBDR or placebo twice daily (300 mg for ≤65 kg, 375 mg for >65-80 kg, 450 mg for >80 kg) for 52 weeks...
January 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28065744/efficacy-and-safety-of-glucagon-like-peptide-1-receptor-agonists-in-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis
#6
Yajie Dong, Qingguo Lv, Sheyu Li, Yuan Wu, Ling Li, Juan Li, Fang Zhang, Xin Sun, Nanwei Tong
BACKGROUND AND OBJECTIVE: New drugs are urgently needed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The aim of this meta-analysis was to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in NAFLD/NASH. METHODS: We searched the MEDLINE, Embase, and Cochrane Library Central to identify randomized controlled trials (RCTs) and observational studies that compared GLP-1RAs with a control treatment or baseline values with respect to efficacy and safety in patients with NAFLD/NASH...
January 5, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/28052629/pathology-of-non-alcoholic-fatty-liver-disease
#7
REVIEW
Pierre Bedossa
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis (Non-alcoholic Fatty Liver or NAFL) to a complex pattern with hepatocellular injury and inflammation (non-alcoholic steatohepatitis; NASH) in the absence of alcohol intake. However, it is increasingly clear that intermediate patterns may exist. The histopathological evaluation of liver biopsy samples is central in the diagnosis of NAFLD and NASH in the absence of sufficiently accurate non-invasive tests because a precise definition of each group is a key issue...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28033294/the-expression-of-thymosin-%C3%AE-4-in-chronic-hepatitis-b-combined-nonalcoholic-fatty-liver-disease
#8
Jing Liang, Wenjuan Cai, Tao Han, Li Jing, Zhe Ma, Yingtang Gao
The aim of the study was to detect the expression level of thymosin β4 (Tβ4) in serum and tissues of patients with chronic hepatitis B (CHB) combined nonalcoholic fatty liver disease (NAFLD). The effects of Tβ4 in hepatic steatosis, chronic inflammation, and fibrosis development in CHB combined NAFLD patients were also discussed. The study included 46 patients in the case group with CHB and NAFLD and 42 patients in the control group with CHB. ELISA was applied to detect serum Tβ4 and TNF-α level. Furthermore, the correlation analysis of Tβ4 levels with biochemical index, pathological index, and TNF-α level was performed...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28028821/sarcopenia-is-associated-with-severe-liver-fibrosis-in-patients-with-non-alcoholic-fatty-liver-disease
#9
S Petta, S Ciminnisi, V Di Marco, D Cabibi, C Cammà, A Licata, G Marchesini, A Craxì
BACKGROUND: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD). AIM: To test the prevalence of sarcopenia and its relation with the severity of fibrosis (main outcome) and the entire spectrum of liver histology in patients with NAFLD. METHODS: We considered 225 consecutive patients with histological diagnosis of NAFLD (Kleiner score)...
December 27, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28003718/histological-evaluation-of-non-alcoholic-fatty-liver-disease-and-its-correlation-with-different-noninvasive-scoring-systems-with-special-reference-to-fibrosis-a-single-center-experience
#10
Mitali M Rath, Manas K Panigrahi, Kaumudee Pattnaik, Pallavi Bhuyan, Sanjib K Kar, Bijay Misra, Debasis Misra, Chudamani Meher, Omprakash Agrawal, Jayshree Rath, Shivaram P Singh
BACKGROUND: Although liver biopsy remains the gold standard for the diagnosis of non-alcoholic fatty liver disease [NAFLD], many non-invasive markers of liver fibrosis have recently been proposed and assessed as surrogates of liver biopsy. AIMS AND OBJECTIVE: To evaluate the degree of liver fibrosis by different non-invasive fibrosis scoring systems and to compare each non-invasive fibrosis scoring system with histological fibrosis stage. MATERIALS AND METHODS: The study population consists of consecutive patients with biopsy proven NAFLD...
December 2016: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/27992443/pro-inflammatory-cytokines-but-not-endotoxin-related-parameters-associate-with-disease-severity-in-patients-with-nafld
#11
Johannie du Plessis, Hannelie Korf, Jos van Pelt, Petra Windmolders, Ingrid Vander Elst, An Verrijken, Guy Hubens, Luc Van Gaal, David Cassiman, Frederik Nevens, Sven Francque, Schalk van der Merwe
Intestinal dysbiosis and elevated lipopolysaccharides (LPS) levels have been implicated in the development of obesity, insulin resistance and non-alcoholic steatohepatitis (NASH). In order to determine if LPS levels are elevated in patients with NASH compared to patients with non-alcoholic fatty liver (NAFL) and, if elevated LPS levels correlated with histological severity of non-alcoholic fatty liver disease (NAFLD) we compared LPS, markers of LPS bioactivity and pro-inflammatory cytokines/chemokines in patients undergoing bariatric surgery...
2016: PloS One
https://www.readbyqxmd.com/read/27936280/application-of-the-combined-fibrometer-vcte-algorithm-in-chinese-patients-with-nonalcoholic-fatty-liver-disease
#12
Thomson Chi-Wang Loong, Jeremy Lok Wei, Jonathan Chung-Fai Leung, Grace Lai-Hung Wong, Sally She-Ting Shu, Angel Mei-Ling Chim, Anthony Wing-Hung Chan, Paul Cheung-Lung Choi, Yee-Kit Tse, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
BACKGROUND AND AIM: The FM VCTE is a new formula combining the serum test FibroMeter (FM) and liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE). We tested the accuracy and utility of FM VCTE for fibrosis staging in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: 215 NAFLD patients with LSM, FM NAFLD, FM VCTE and other serum tests (aspartate aminotransferase [AST]-to-platelet ratio index, FIB-4 index, BARD score, NAFLD fibrosis score and AST-to-alanine aminotransferase ratio) performed 1 day before liver biopsy were evaluated...
December 9, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27936091/development-of-serum-marker-models-to-increase-diagnostic-accuracy-of-advanced-fibrosis-in-nonalcoholic-fatty-liver-disease-the-new-linki-algorithm-compared-with-established-algorithms
#13
Byron Lykiardopoulos, Hannes Hagström, Mats Fredrikson, Simone Ignatova, Per Stål, Rolf Hultcrantz, Mattias Ekstedt, Stergios Kechagias
BACKGROUND AND AIM: Detection of advanced fibrosis (F3-F4) in nonalcoholic fatty liver disease (NAFLD) is important for ascertaining prognosis. Serum markers have been proposed as alternatives to biopsy. We attempted to develop a novel algorithm for detection of advanced fibrosis based on a more efficient combination of serological markers and to compare this with established algorithms. METHODS: We included 158 patients with biopsy-proven NAFLD. Of these, 38 had advanced fibrosis...
2016: PloS One
https://www.readbyqxmd.com/read/27922486/the-post-transplant-course-of-patients-undergoing-liver-transplantation-for-nonalcoholic-steatohepatitis-versus-cryptogenic-cirrhosis-a-retrospective-case-control-study
#14
Lukas W Unger, Merima Herac, Katharina Staufer, Andreas Salat, Gerd Silberhumer, Michael Hofmann, Michael Trauner, Susanne Rasoul-Rockenschaub, Thomas Soliman, Thomas Reiberger, Gabriela A Berlakovich
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) can be considered the hepatic manifestation of the metabolic syndrome with nonalcoholic steatohepatitis (NASH) as its progressive form. With increasing prevalence of the metabolic syndrome, NASH cirrhosis is becoming a leading cause for liver transplantation. Some cases of orthotopic liver transplantation (OLT) due to cryptogenic cirrhosis (CC) might show typical features of NASH cirrhosis. Therefore, our aim was to assess recurrence of liver fibrosis in patients transplanted for NASH versus CC after OLT...
March 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27911262/magnetic-resonance-elastography-vs-transient-elastography-in-detection-of-fibrosis-and-noninvasive-measurement-of-steatosis-in-patients-with-biopsy-proven-nonalcoholic-fatty-liver-disease
#15
Charlie C Park, Phirum Nguyen, Carolyn Hernandez, Ricki Bettencourt, Kimberly Ramirez, Lynda Fortney, Jonathan Hooker, Ethan Sy, Michael T Savides, Mosab H Alquiraish, Mark A Valasek, Emily Rizo, Lisa Richards, David Brenner, Claude B Sirlin, Rohit Loomba
BACKGROUND & AIMS: Magnetic resonance imaging (MRI) techniques and ultrasound-based transient elastography (TE) can be used in noninvasive diagnosis of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD). We performed a prospective study to compare the performance of magnetic resonance elastography (MRE) vs TE for diagnosis of fibrosis, and MRI-based proton density fat fraction (MRI-PDFF) analysis vs TE-based controlled attenuation parameter (CAP) for diagnosis of steatosis in patients undergoing biopsy to assess NAFLD...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27881858/safety-and-efficacy-of-bariatric-surgery-in-patients-with-advanced-fibrosis
#16
T Singh, G S Kochhar, G B Goh, P Schauer, S Brethauer, M Kroh, A Aminian, R Lopez, S Dasarathy, A J McCullough
BACKGROUND: Bariatric surgery is performed safely in non-alcoholic fatty liver disease (NAFLD) patients with minimal fibrosis (stage 1-2). However, the safety and potential benefits of bariatric surgery for NAFLD with advanced fibrosis (stage 3-4) remain unclear. This study was designed to compare the safety and efficacy of bariatric surgery in patients with biopsy proven advanced fibrosis to those with minimal fibrosis. METHODS: All patients who underwent bariatric surgery between 2005 and 2014 and had evidence of NAFLD with fibrosis score 3-4 (advanced fibrosis) based on the staging system defined by Kleiner et al...
December 20, 2016: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/27872651/a-review-of-western-and-traditional-chinese-medical-approaches-to-managing-nonalcoholic-fatty-liver-disease
#17
REVIEW
Wei-Fan Hsu, Lee-Yan Sheen, Hung-Jen Lin, Hen-Hong Chang
Nonalcoholic fatty liver disease (NAFLD) is a disease of attention because of increase in prevalence from 20% to 41%. The clinical and pathological conditions in patients with NAFLD range from steatosis alone to nonalcoholic steatohepatitis (NASH) with or without fibrosis to hepatic cancer. In the United States, NAFLD was the second-leading indication for liver transplant between 2004 and 2013. Although imaging studies such as magnetic resonance elastography and the use of diagnostic panels and scoring systems can provide a fairly accurate diagnosis of NAFLD, there are few treatment options for patients with mild to moderate disease other than lifestyle modification...
2016: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/27859583/external-validation-of-the-nonalcoholic-fatty-liver-disease-fibrosis-score-for-assessing-advanced-fibrosis-in-korean-patients
#18
Dae Won Jun, Sang Gyune Kim, Sang Hoon Park, So-Young Jin, Ji Sung Lee, Jin-Woo Lee, Moon Young Kim, Dae Hee Choi, Yong Kyun Cho, Jong Eun Yeon, Joo Hyun Sohn
BACKGROUND: The degree of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) is a critical predictive factor for patient prognosis. This study was intended to perform external validation of the various fibrosis prediction models for assessing advanced fibrosis in Korean NAFLD patients. METHODS: A retrospective study of 412 patients with NAFLD confirmed by liver biopsy in hospitals affiliated with the Koran NAFLD study group was conducted and the predictive ability of existing liver fibrosis prediction models including NAFLD fibrosis score (NFS), BARD, and FIB-4 were compared...
November 11, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27851786/calcium-reduces-liver-injury-in-mice-on-a-high-fat-diet-alterations-in-microbial-and-bile-acid-profiles
#19
Muhammad Nadeem Aslam, Christine M Bassis, Li Zhang, Sameer Zaidi, James Varani, Ingrid L Bergin
A high-fat "Western-style" diet (HFWD) promotes obesity-related conditions including non-alcoholic steatohepatitis (NASH), the histologic manifestation of non-alcoholic fatty liver disease (NAFLD). In addition to high saturated fat and processed carbohydrates, the typical HFWD is deficient in calcium. Calcium-deficiency is an independent risk factor for many conditions associated with the Western-style diet. However, calcium has not been widely evaluated in the context of NAFLD. The goal of the present study was to determine if dietary calcium supplementation could protect mice fed a HFWD from NAFLD, specifically by decreasing non-alcoholic steatohepatitis (NASH) and its down-stream consequences...
2016: PloS One
https://www.readbyqxmd.com/read/27830836/long-term-lifestyle-interventions-in-middle-aged-and-elderly-men-with-nonalcoholic-fatty-liver-disease-a-randomized-controlled-trial
#20
Fangyuan Dong, Yan Zhang, Yiqin Huang, Yiqian Wang, Gansheng Zhang, Xiaona Hu, Jiaofeng Wang, Jie Chen, Zhijun Bao
Nonalcoholic fatty liver disease (NAFLD), a metabolic disorder related to insulin resistance and metabolic syndrome, has become a public health concern. Currently, the principal therapeutic modalities targeting NAFLD are lifestyle interventions. However, the efficacy of long-term lifestyle interventions in managing NAFLD remains largely unexplored. This study aimed to evaluate the efficacy of long-term lifestyle interventions in middle-aged and elderly men with NAFLD. All 280 eligible patients were randomized to the control or test group...
November 10, 2016: Scientific Reports
keyword
keyword
112750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"